Skip to search formSkip to main contentSkip to account menu

ARC 1779

Known as: ARC-1779, ARC1779 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Aptamers, Nucleotide
ULvWF Multimer-targeting Agent ARC1779

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
Initial experience from a double‐blind, placebo‐controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura
quency counts and percentages. Continuous variables were summarized using one or more of the following: mean, standard deviation… 
Highly Cited
2012
Highly Cited
2012
The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease.
Blockade of hyperactive von Willebrand factor (VWF) by ARC1779 blunted the platelet drop induced by desmopressin in patients with… 
Highly Cited
2011
Highly Cited
2011
A dose ranging phase I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombocytopenic purpura.
Congenital thrombotic thrombocytopenic purpura (TTP) is a very rare but potentially life-threatening disorder. This phase I/II… 
Highly Cited
2011
Highly Cited
2011
Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura.
Thrombotic thrombocytopenic purpura (TTP) can cause severe organ damage due to enhanced platelet aggregation by ultra-large von… 
Review
2010
Review
2010
Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases
Platelet inhibitors are the mainstay treatment for patients with vascular diseases. The current ‘gold standard’ antiplatelet… 
Highly Cited
2010
Highly Cited
2010
A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease.
Desmopressin aggravates thrombocytopenia in type 2B von Willebrand disease (VWF type 2B) by release of large and hyper-adhesive… 
Highly Cited
2009
Highly Cited
2009
Inhibition of von Willebrand factor‐mediated platelet activation and thrombosis by the anti‐von Willebrand factor A1‐domain aptamer ARC1779
Summary.  Background: von Willebrand factor (VWF) has a role in both hemostasis and thrombosis. Platelets adhere to damaged… 
Highly Cited
2009
Highly Cited
2009
Anti–von Willebrand factor aptamer ARC1779 for refractory thrombotic thrombocytopenic purpura
BACKGROUND: Plasma exchange is the main therapy for thrombotic thrombocytopenic purpura (TTP). No treatments other than plasma… 
Review
2008
Review
2008
Von Willebrand Factor in Cardiovascular Disease: Focus on Acute Coronary Syndromes
von Willebrand factor (VWF) plays a pivotal role in platelet adhesion and aggregation at sites of high shear rates (eg, in… 
Highly Cited
2007
Highly Cited
2007
First-in-Human Evaluation of Anti–von Willebrand Factor Therapeutic Aptamer ARC1779 in Healthy Volunteers
Background— ARC1779 is a therapeutic aptamer antagonist of the A1 domain of von Willebrand Factor (vWF), the ligand for receptor… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License